|
1. Amerian M, Sohrabi MB, Zolfaghari P,Yarmohammadi M, Nezakati E, et al. Effects of niasine on serum phosphorus, PTH and lipid profile in the hemodialysis patients in Shahroud city. Med Sci J Islamic Azad Univ Tehran Med Branch 2015; 24(4): 221-6. 2. Berns JS. Niacin and related compounds for treating hyperphatemia in dialysis patients. Semin Dial 2008; 21(3): 203-5. 3. Fukagawa M, Nakanishi S, Kazama JJ. Basic and clinical aspect of parathyroid hyperplasia in chronic kidney disease. Kidney Int Suppl 2006; (102): S3-7. 4. Dusso AS, Sato T, Arcidiacono MV, Alvarez-Hernandez D, Yang J, Gonzalez-Suarez I, et al. Pathogenic mechanisms for parathyroid hyperplasia. Kidney Int Suppl 2006; (102): S8-11. 5. Bellasi A, Kooienga L, Block GA. Phosphate binders: new products and challenges. Hemodial Int 2006; 10(3): 225-34. 6. Foley RN, Murray AM, Li S, Herzog CA, McBean AM, Eggers PW, et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the united states medicare population, 1998 to 1999. J Am Soc Nephrol 2005; 16(2): 489-95. 7. Damment SJ, Pennick M. Clinical pharmacokinetics of the phosphate binder lanthanum carbonate. Clin Pharmacokinet 2008; 47(9): 553-63. 8. Joki N. [Pharmacodynamic and pharma-cokinetic profile f lanthanum carbonate]. Clin Calcium 2009; 19(2): 213-8. 9. Albaaj F, Hutchison AJ. Anthanum carbonate (Fosrenol): a novel agent for the treatment of hyperphosphataemia in renal failure and dialysis patients. Int J Clin Pract 2005; 59(9): 1091-6. 10. Eto N, Miyata Y, Ohno H, Yamashita T. Nicotinamide prevent the development of hyperphosphataemia by suppressing intestinal sodium-dependent phosphate transporter in rats with adenina-induced renal failure. Nephrol Dial Transplant 2005; 20(7): 1378-84. 11. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15(8): 2208-18. 12. Debiec H, Lorenc R. Identification of Na, Pi-binding protein in kidney and intestinal brush-border membranes. Biochem J 1988; 255(1): 185-91. 13. Field J, Zhang Li, Brun KA, Brooks DP, Edwards RM. Cloning and functional characterization of a sodium dependent phosphate transporter expressed in human lung and small intestine. Biochem Biophys Res Commun 1999; 258(3): 578-82. 14. Coppolino G, Lucisano S, Rivoli L, Fuiano G, Villari A, Villari I, et al. Sevalamer Hydrochloride, Sevelamer Carbonate and Lanthanum Carbonate: In Vitro and In Vivo Effects on Gastric Environment. Ther Apher Dial 2015; 19(5): 471-6. 15. Komaba H, Kakuta T, Suzuki H, Hida M, Suga T, Fukagawa M. Urvival advantage of lanthanum carbonate for hemodialysis patients with uncontrolled hyperphosphatemia. Nephrol Dial Transplant 2015; 30(1): 107-14. 16. Takahara Y, Matsuda Y, Takahashi S, Shigematsu T. Efficacy and safety of lanthanum carbonate in pre-dialysis CKD patients with hyperphosphatemia: a randomized trial. Clin Nephrol 2014; 82(3): 181-90. 17. Liu L, Wang Y, Chen H, Zhu X, Zhou L, Yang Y. The effects of non-calcium-based phosphate binders versus calcium-based phosphate binders on cardiovascular calcification and bone remodeling amongdialysis patients: a meta-analysis of randomized trials. Ren Fail 2014; 36(8): 1244-52. 18. Zhang C, Wen J, Li Z, Fan J. Efficacy and safety of lanthanum carbonate on chronic kidney disease-mineral and bone disorder in dialysis patients: a systematic review. BMC Nephrol 2013 17; 14: 226. 19. Okamoto H, Haruhara K, Kamejima S, Mafune H, Manabe M, Kanzaki G, et al. Is granular formulation of lanthanum carbonate more effective than chewable tablets? Ther Apher Dial 2014; 18 Suppl 1: 23-7. 20. Hyodo T, Kawakami J, Mikami N, Wakai H, Ishii D, Yoshida K, et al. Increase in the dosage amount of vitamin D3 preparations by switching from calciumcarbonate to lanthanum carbonate. Ther Apher Dial 2014; 18 Suppl 1: 14-7. 21. Kishi Y, Obara Y, Hara K, Yamashiro H, Kurosawa N, Takada D. Clinical effects of long-term (36-month) lanthanum carbonate administration inhemodialysis patients in Japan. Ther Apher Dial 2014; 18 Suppl 1: 9-13. 22. Shimoda K, Akiba T, Matsushima T, Rai T, Abe K, Hoshino M. Niceritrol decreases serum phosphate levels in hemodialysis patients. Nihon Jinzo Gakkai Shi 1998; 40(1): 1-7. 23. Freemont AJ. Lanthanum carbonate. Drugs Today 2006; 42(12):759-70. 24. Hatakeyama S, Murasawa H, Narita T, Oikawa M, Fujita N, Iwamura H, et al. Switching hemodialysis patients from sevelamer hydrochloride to bixalomer: a single-center, non-randomized analysis of efficacy and effects on gastrointestinal symptoms and metabolic acidosis. BMC Nephrol 2013; 14: 222. 25. Kuboyama N, Watanabe Y, Yamaguchi M,Sato K, Suzuki T, Akiba T. Effects of niceritrol on faecal and urinary phosphate excretion in normal rats. Nephrol Dial Transplant 1999; 14(3): 610-4. 26. Hattenhauer O, Traebert M, Murer H, Biber J. Regulation of small intestinal Na-Pi type IIb cotransporter by dietary phosphate intake. Am J Physiol 1999; 277(4 Pt 1): G756-62.
|
.png){kind=logo}
